drugset
drugset / Trial / NCT03478319

A Study of ACE-2494 in Healthy Subjects

NCT03478319 ↗

Phase 1 Completed 48 enrolled Acceleron Pharma, Inc.
RandomizedParallel-groupTriple-blindOther

Summary

The purpose of the study is to assess safety, tolerance, pharmacokinetic, and pharmacodynamics of single doses of ACE-2494 in healthy postmenopausal women.

Timeline

Start
2018-02-15
Primary completion
2019-06-13
Completion
2019-06-17

Drugs

EvaluationDrugModalityDoseRoute
Subject ACE-2494 Protein / enzyme biologic 0.06 mg/kg Subcutaneous
Subject ACE-2494 Protein / enzyme biologic 0.2 mg/kg Subcutaneous
Subject ACE-2494 Protein / enzyme biologic 0.6 mg/kg Subcutaneous
Subject ACE-2494 Protein / enzyme biologic 1 mg/kg Subcutaneous
Subject ACE-2494 Protein / enzyme biologic 2 mg/kg Subcutaneous

Indications

No indication recorded.